| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | AZD6244 | CCLE | pan-cancer | AAC | -0.02 | 0.7 |
| mRNA | L-685458 | CCLE | pan-cancer | AAC | 0.019 | 0.7 |
| mRNA | AZD0530 | CCLE | pan-cancer | AAC | 0.014 | 0.8 |
| mRNA | Topotecan | CCLE | pan-cancer | AAC | 0.005 | 0.9 |
| mRNA | ciclosporin | CTRPv2 | pan-cancer | AAC | 0.16 | 2e-05 |
| mRNA | sirolimus:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.13 | 0.0002 |
| mRNA | Rapamycin | CTRPv2 | pan-cancer | AAC | 0.13 | 0.0002 |
| mRNA | MK-2206 | CTRPv2 | pan-cancer | AAC | 0.13 | 0.0004 |
| mRNA | AZD8055 | CTRPv2 | pan-cancer | AAC | 0.11 | 0.002 |
| mRNA | GDC-0941 | CTRPv2 | pan-cancer | AAC | 0.11 | 0.002 |